Outbreak of KPC-2 producing *Serratia marcescens* MDR in a tertiary hospital in the Midwest region, Brazil

Thalita Priscila Peres Seabra da Cruz

ORCID: https://orcid.org/0000-0002-0167-6710

Universidade Federal de Mato Grosso, Brazil

E-mail: thaly.pri@hotmail.com

Francisco Kennedy Scofoni Faleiros de Azevedo

ORCID: https://orcid.org/0000-0003-0477-9501

Universidade Federal de Mato Grosso, Brazil

E-mail: fksfazevedo@gmail.com

Marco Andrey Pepato

ORCID: https://orcid.org/0000-0002-7896-6329

Universidade Federal de Mato Grosso, Brazil

E-mail: mcoandrey@gmail.com

Alessandra Tammy Hayakawa Ito de Sousa

ORCID: https://orcid.org/0000-0002-7524-2173

Universidade Federal de Mato Grosso, Brazil

E-mail: tammyhito@gmail.com

Paula Sossai Rizzo

ORCID: https://orcid.org/0000-0003-0934-5139

Universidade Federal de Mato Grosso, Brazil

E-mail: paulasossai@yahoo.com.br

Francisco José Dutra Souto

ORCID: https://orcid.org/0000-0002-2529-4119

Universidade Federal de Mato Grosso, Brazil

E-mail: fsouto@gmail.com

Luciano Nakazato

ORCID: https://orcid.org/0000-0002-1244-0690

Universidade Federal de Mato Grosso, Brazil

E-mail: lucnaka@gmail.com

Valéria Dutra

ORCID: https://orcid.org/0000-0002-6630-2293

Universidade Federal de Mato Grosso, Brazil

E-mail: valeriadutra.dutra@gmail.com

Abstract

About 700,000 deaths per year worldwide are caused by Healthcare-related infections (HAI). Result in significant patient morbidity and mortality, being is ranked the fourth leading cause of death in Brazil. Usually, HAI are caused by multidrug-resistant microorganisms (MDR), as well as *Serratia marcescens*, that is associated with healthcare-related infections causing high patient mortality and morbidity. This paper describes an outbreak of *S. marcescens* MDR carrier gene *bla*KPC-2 in a university hospital, with the need to broadly combat horizontal transmission of this bacterium between patients, as well as the need to optimize treatment with other antimicrobial classes due to resistance of this microorganism to polymyxins. Ten isolates were analyzed for the presence of carbapenemic resistance gene *bla*KPC-2. This gene was detected in all isolates, with a corresponding high patient mortality rate, highlighting the importance of its molecular detection, which corroborates the resistance of *S. marcescens* to carbapenem antibiotics. The detection of this gene is necessary due to the importance to broadly combat horizontal transmission of this bacterium between patients, as well as the need to optimize treatment with other antimicrobial agents due to its resistance to polymyxins.

**Keywords:** *S. marcescens*; Health-related infection; Outbreak; *Bla*KPC.
Resumo
Cerca de 700,000 mortes por ano em todo o mundo são causadas por infecções relacionadas à saúde (IRA). Resultam em significativa morbimortalidade de pacientes, sendo classificada como a quarta maior causa de óbito no Brasil. Geralmente, as IRAS são causadas por microorganismos multirresistentes a antimicrobianos (MDR), assim como *Serratia marcescens*, que está associada a infecções relacionadas à saúde, causando alta mortalidade e morbidade dos pacientes. Este trabalho descreve um surto causado por *S. marcescens* MDR portadora do gene blaKPC-2 em um hospital universitário, com a necessidade de combater amplamente a transmissão horizontal dessa bactéria entre os pacientes, bem como a necessidade de otimizar o tratamento com outras classes de antimicrobianos devido à resistência deste microrganismo às polimixinas. Dez isolados foram analisados quanto à presença do gene de resistência carbapenêmico *bla*KPC-2. Este gene foi detectado em todos os isolados, com correspondente taxa de mortalidade alta dos pacientes, evidenciando a importância de sua detecção molecular, que corrobora com a resistência de *S. marcescens* aos antibióticos carbapenêmicos. A detecção deste gene faz-se necessária devido à importância de combater amplamente a transmissão horizontal dessa bactéria entre os pacientes, bem como a necessidade de otimizar o tratamento com outros antimicrobianos devido à sua resistência às polimixinas.

**Palavras-chave:** *S. marcescens*; Infecção relacionada à saúde; Surto; *Bla*KPC.

Resumen
Aproximadamente 700,000 muertes por año en todo el mundo son causadas por infecciones asociadas a atención de salud (IAAS) las cuales resultan en significativa morbimortalidad de pacientes. Como consecuencia estas infecciones son clasificadas como la cuarta mayor causa de muertes en Brasil. Generalmente, las IAAS, son causadas por microorganismos multirresistentes a los antimicrobianos (MDR, del inglés multidrug-resistance), así como el *Serratia marcescens*, que está asociado a infecciones relacionadas a la atención intrahospitalar. Este estudio describe un brote causado por *S. marcescens* multirresistente portadora del gen *bla*KPC-2 en un hospital universitario. Delante de la necesidad de combatir eficazmente la transmisión horizontal de esta bactéria entre los pacientes y también la necesidad de optimizar el tratamiento con otras clases de antimicrobianos debido a la resistencia de este microrganismo a las polimixinas, fueron analizadas diez muestras en relación a la presencia del gen de resistencia carbapenêmico *bla*KPC-2. Este gen fue detectado en todas las muestras con tasa de mortalidad alta, evidenciando la importancia de su detección molecular, además de corroborarse la resistencia de *S. marcescens* a los antibióticos carbapenémicos. Este estudio se hace necesaria debido a la importancia de combatir la transmisión horizontal de la bactéria entre los pacientes, como también es importante mejorar el tratamiento con otros antimicrobianos delante de la resistencia a las polimixinas.

**Palabras clave:** *S. marcescens*; Infección asociadas a atención de salud; Brote; *Bla*KPC.

1. Introduction

Healthcare-related infections (HAI) are considered a serious medical and social problem, resulting in significant patient morbidity and mortality. They are caused by multidrug-resistance microorganisms (MDR), causing about 700,000 deaths per year worldwide, and may reach ten million by the year 2050 (IACG, 2019). In developing countries, HAI may be up to 20 times higher than in developed countries (Allegranzi et al., 2011). In Brazil, HAI occupy the fourth leading cause of death (Silva & Lincopan, 2012).

*Serratia marcescens* (*S. marcescens*) can be isolated in the skin, tracheal secretion, urine and feces of critically ill patients, also found in contaminated invasive medical devices, intravenous and topical solutions, liquid soaps and intensive care unit (ICU) air conditioning, favoring the emergence of colonization of patients and hospital outbreaks (Polilli, et al., 2011). According to Quezada-Aguiluz et al. (2020), this opportunistic pathogen of interest to public health has been neglected, even with high rates of antimicrobial resistance.

*S. marcescens* stands out for its intrinsic and acquired resistance to a variety of antibiotic classes, including β-lactams, aminoglycosides, quinolones, macrolides and polypeptides (Sandner-Miranda et al., 2016). Thus, the drugs that present greater efficacy in the treatment of infections caused by multiresistant Gram-negative bacteria are the carbapenems however, there has been an increase in resistance rates to these antibiotics in recent years in this group (Cristina et al., 2019), which can be explained by the fact that carbapenemase (KPC) genes are often inserted through conjugative plasmids, which makes *S.*
S. marcescens resistant to carbapenems, causing great concern for the reduction of therapeutic options in AIH (Silva et al., 2015).

This study describes the outbreak of S. marcescens MDR carrier gene blaKPC-2 in a university hospital, with the need to broadly combat horizontal transmission of this bacterium between patients, as well as the need to optimize treatment with other antimicrobial classes due to resistance of this microorganism to polymyxins.

2. Methodology

A total of ten isolates were obtained from ten ICU patients, medical and surgical wards of a tertiary public university hospital in Cuiabá, Mato Grosso, Brazil's Midwestern Region, which has 118 beds. Samples were collected from patients as hospital routine between September and December 2018 (Table 1). The identification of S. marcescens of the samples was performed in the Vitek2 system (BioMérieux, Marcy l'Etoile, França) and confirmed by the MALDI-TOF technique (Matrix Associated Laser Desorption-Ionization – Time of Flight).

Table 1: Patient clinical data: Age, sex and underlying disease of the patients included in the study; Sample type; Patient's situation and place of admission; Length of stay; Outcome of the patient.

| Patient’s age (years), sex, underlying disease | Type of sample | Patient situation and location of hospital admission | Time to hospitalization (days) | Outcome |
|-----------------------------------------------|----------------|-------------------------------------------------|-------------------------------|---------|
| 74, M, neurocryptococcosis                     | Aspirated tracheal | MVAP *, adult ICU**                              | 84                           | Death   |
| 84, F, acute myocardial infarction             | Aspirated tracheal | MVAP *, medical clinic ward                       | 53                           | Death   |
| 60, M, adenocarcinoma of prostate              | Tip of catheter   | Colonization, ambulatory                          | Not hospitalized              | Cure    |
| 63, F, leprosy                                 | Rectal swab       | Sepse, medical clinic ward                        | 27                           | Cure    |
| 57, M, pulmonary aspergillosis                 | Pleural liquid    | Pneumonia, medical clinic Ward                    | 36                           | Cure    |
| 71, M, HIV and pneumocystosis                  | Aspirated tracheal | Pneumonia, ICU**                                 | 61                           | Death   |
| 40, F, leprosy and cholecystitis               | Rectal swab       | Colonization, ICU** and Clinic Surgical ward     | 30                           | Cure    |
| 56, M, diaphragmatic hernia and emergency laparotomy | Abdominal secretion | Intrabdominal infection, clinical Surgical ward and ICU | 49       | Cure    |
| 18, M, hemolytic anemia and disseminated histoplasmosis | Synovial Liquid | Septic elbow arthritis, medical clinic ward | 85 | Cure    |
| 65, M, pemphigus foliaceus and dialytic renal failure | Blood | Bloodstream infection, ICU | 33 | Death   |

* MVAP: mechanical ventilation-associated pneumonia
** ICU: intensive care unit (ICU)
Source: Authors.

Susceptibility profiles were based on Minimum Inhibitory Concentration (MIC) by Bact / Alert 3D and Vitek2 (BioMérieux, Marcy l'Etoile, France), where seven classes of antimicrobials were tested. Isolates were classified as sensitive,
resistant, or intermediate sensitive according to Clinical & Laboratory Standards Institute Guidelines (CLSI, 2017).

Genomic DNA extraction from isolates was performed by the phenol-chloroform method according to Sambrook and Russel (2004). The extracted DNAs were submitted to PCR of the KPC-2 carbapenemase resistance gene. The oligonucleotide sequence used was that described by Yigitì et al. (2001). Subsequently, the PCR product was purified with the GE Healthcare Life Sciences illusstra ExoProStar Kit and used in the sequencing reaction along with the BigDye Terminator Ready Reaction Cycle Sequencing (Applied Biosystems) in auto sequencer 3500 Genetic Analyzer (Applied Biosystems).

3. Results and Discussion

Of the ten patients, six were male (60%) and four female (40%). The average age of the patients was 58.8 (± 18.56) years. The clinical data of the patients are described in Table 1, and the patients presented severe intercurrent diseases demonstrating the opportunistic infection character of S. marcescens (PoliÌli et al., 2011).

In this study, the mortality rate was 40% (4/10), similar to other reports that varied from 14 to 60% (Arslan et al., 2010; Milisavljevic et al., 2004), requiring a larger study relating the search for resistance genes of isolates and mortality, as HAI along with antimicrobial resistance, especially carbapenem resistance, increase patient mortality and morbidity rates, as well as their costs and length of stay (Kaleem et al., 2010).

The isolates showed in vitro resistance to the following antimicrobial classes: penicillins (piperacillin / tazobactam n=10, 100%), cephalosporins (cefepime n=10, 100%), carbapenemics (imipenem n=10, 100%; meropenem n=10, 100%; ertapenem n=10, 100%), quinolones (ciprofloxacin n=10, 100%), polymyxins (polymyxin B n=10, 100%). The emergence of antimicrobial resistance in S. marcescens is preceded by widespread use of the antibiotic in hospital settings such as beta-lactams, aminoglycosides, fluoroquinolones (Jones, 1998; Hejazi & Falkiner, 1997) and colistin (Silva et al., 2015). In relation to aminoglycosides, 100% were resistant to amikacin and 10% to gentamicin. This difference may be associated with the occurrence of the gene pREM-1 [aac (6’)-30] conferring reduced susceptibility to amikacin and not gentamicin (Mendes et al. 2004).

The best result was glycylcyclines (tigecycline) with only 20% resistance, however the occurrence of SdeXY-HasF efflux pumps in S. marcescens decreases their activity as well as gallbladder excretion that may make treatment difficult of urinary infections (Hornsey, 2010; Peleg & Hooper, 2010).

Only one patient was resistant to all classes of antimicrobials. In addition to this, two patients had intermediate sensitivity to tigecycline and one patient with intermediate sensitivity to gentamicin, gentamicin and tigecycline being the only antimicrobials to which isolates were susceptible. All patients who died had susceptibility to gentamicin and tigecycline, except one patient who had intermediate sensitivity to gentamicin (Table 2).
Table 2: Classes of antibiotics, antimicrobial used and their respective microbial resistance rates (%).

| Antimicrobial Classes | Antibiotic         | Resistance |
|-----------------------|--------------------|------------|
| **Penicillins**       | Piperacillin + tazobactam | 100% (10/10) |
| **Cephalosporins**    | Cefepime           | 100% (10/10) |
| **Carbapenem**        | Imipenem           | 100% (10/10) |
|                       | Meropenem          | 100% (10/10) |
|                       | Ertapenem          | 100% (10/10) |
| **Quinolones**        | Ciprofloxacin      | 100% (10/10) |
| **Polymyxins**        | Polymyxin B        | 100% (10/10) |
| **Aminoglycosides**   | Gentamicin*        | 20% (2/10)*  |
| **Glycyclines**       | Tigecycline*       | 30% (3/10)*  |

*The intermediate sensitivity isolates were considered resistant.

Source: Authors.

**All carbapenem blaKPC-2 gene observed in all (Figure 1), with meropenem ertapenem phenotypes.**

Due to the intrinsic resistance of *S. marcescens* to polymyxins (Silva et al. 2015; Denervaud-Tendon et al., 2017), finding the presence of carbapenemases becomes essential for the choice of the most appropriate antibiotics in order to achieve therapeutic success.

The bacteria of the Enterobacteriaceae family that extended-spectrum β-lactamase producing and resistant to carbapenem antibiotics have been classified by the World Health Organization (WHO) as critical pathogens for which further research is urgently needed (Tacconelli et al., 2018). In Brazil, other genes such as blaIMP-10, blaSME-4 and blaTEM1 have also been described, emphasizing the need for investigation of carbapenemic resistance genes due to the great importance of this antimicrobial class in the treatment of, especially in a healthcare setting where carbapenems are primarily used as a last-line treatment for gram-negative MDR bacterial infections HAI (Cayô et al. 2017; Margate et al. 2015; Silva et al. 2015).

**Figure 1:** Amplification of the KPC-2 gene fragment (1011bp) in all isolates (1-10); M: marker (Ladder 100bp); CN: negative control; CP: positive control.

Source: Personal archive.
4. Conclusion

We observed that S. marcescens isolates from this study caused high mortality with high resistance profile. Thus, genomic studies should be performed in order to clarify whether such microorganisms are clonal in Cuiabá, alerting to the importance of S. marcescens in the Midwest region and possibly in other regions of Brazil. It is concluded that rapid detection methods should be performed in reference health units to verify early detection of resistance genes and to improve antimicrobial treatment, reducing the horizontal transfer of antimicrobial resistance genes.

Approvals and ethical statements

The research project was approved by the Research Ethics Committee of the Júlio Muller University Hospital, and was registered with the National System of Ethical Evaluation of Human Research Projects (CAAE 17331119.2.0000.5541).

References

Allegrenzi, B., Bagher Nejad, S., Combescure, C., Graffmans, W., Attar, H., Donaldson, L., & Pittet, D. (2011). Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. *Lancet*, 377 (9761), 228-241. doi: 10.1016/ S0140-6736 (10)6148-4

Arslan, U., Erayman, I., Kirdar, S., Yukselkaya, S., Cimen, O., Tuncer, I., & Bozdogan, B. (2010). *Serratia marcescens* sepsis outbreak in a neonatal intensive care unit. *Pediatrics International*, 52, 208-212. doi: 10.1111/j.1442-200X.2009.02934.x

Cayro, R., Leme, R.C., Streeling, A.P., Matos, A.P., Nodari, C.S., Chaves, J.R., Brandão, J.J., De Almeida, M.F., Carraretto, V., De Castro Pereira, M.A., De Almeida, J.P., Ferreira, D.C., & Gales, A.C. (2017). *Serratia marcescens* harboring SME-4 in Brazil: a silent threat. *Diagnostic Microbiology and Infectious Disease*, 87, 357-358. doi: 10.1016/j.diagmicrobio.2017.01.00

Clinical & Laboratory Standards Institute (CLSI) (2017). “Performance Standards for Antimicrobial Susceptibility Testing: 27th informational supplement M100.” Wayne, PA: Clinical and Laboratory Standards Institute, pp. 46-48.

Cristina, M.L., Sartini, M., & Spagnolo, A.M. (2019). *Serratia marcescens* infections in neonatal intensive care units (NICUs). *International Journal of Environmental Research and Public Health*, 16, (61), 1-10. doi: 10.3390/ijerph16040610

Denervaud-Tendon, V., Poirel, L., Connolly, L.E., Krause, K.M., & Nordmann, P. (2017). Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates. *Journal of Antimicrobial Chemotherapy*, 72 (10), 2787-2791. doi: 10.1093/jac/dkx239

Interagency Coordination Group on Antimicrobial Resistance (IACG) (2019). No time to wait: securing the future from drug-resistant infections. Report to the Secretary-General of the United Nations. https://www.who.int/docs/default-source/documents/no-time-to-wait-securing-the-future-from-drug-resistant-infections-en.pdf?sfvrsn=3b424ad7_6

Hejazi, A., & Falkiner, F.R. (1997). *Serratia marcescens*. *Journal of Medical Microbiology*, 46, 903–912. doi:10.1099/00222615-46-11-903

Homesley, M., Ellington, M.J., Doumith, M., Hudson, S., Livermore, D.M., & Woodford, N. (2010). Tigecycline resistance in *Serratia marcescens* associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and ceftiraxone. *Journal of Antimicrobial Chemotherapy*, 65, 479-482. doi:10.1093/jac/dkp475

Jones, R.N. (1998) Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. *Diagnostic Microbiology and Infectious Disease*, 31, 461–466. doi:10.1016/s0146-8053(98)00029-7

Kaleem, F., Usman, J., Hassan, A., & Khan, A. (2010). Frequency and susceptibility pattern of metallo-beta-lactamase producers in a hospital in Pakistan. *The Journal of Infection in Developing Countries*, 4, 810–813. doi: 10.3855 / jidc.1050

Margate, E., Magalhães, V., Fehlberg, L.C.C., Gales, A.C., & Lopes, A.C.S. (2015). KPC-producing *Serratia marcescens* in a home-care patient from Recife, Brazil. *Revista do Instituto de Medicina Tropical de São Paulo*, 57, 359-360. doi: 10.1590/0036-46652015000400016

Mendes, R.E., Tolemán, M.A., Ribeiro, J., Sader, H.S., Jones, R.N., & Walsh, T.R. (2004). Integron carrying a novel metallo-beta-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6’)-30/aac(6’)-Ib’- report from the SENTRY Antimicrobial Surveillance Program. *Antimicrobial Agents and Chemotherapy*, 48, 4693-4702. doi:10.1128/AAC.48.12.4693-4702.2004

Milisavljevic, V., Wu, F., Larson, E., Rubenstein, D., Ross, B., Drusin, L.M., Della-Latta, P., & Saiman, L. (2004). Molecular epidemiology of *Serratia marcescens* outbreaks in two neonatal intensive care units. *Infection Control & Hospital Epidemiology.*, 25, 719-721. doi:10.1086/502466

Peleg, A.Y., & Hooper, D.C. (2010). Hospital-acquired infections due to gram-negative bacteria. *The New England Journal of Medicine*, 362, 1804-1813. doi:10.1056/NEJMra0904124

Politi, E., Parruti, G., Fazzi, P., D'Antonio, D., Palmieri, D., D’Incecco, C., Mangifesta, A., Garofalo, G., Del Duca, L., D’Amaro, C., Scimia, M., Cortesi, V., & Fortunato, V. (2011). Rapidly controlled outbreak of *Serratia marcescens* infection/colonisations in a neonatal intensive care unit, Pescara General Hospital, Pescara, Italy. *Euro Surveill* 16 (24), 1-3. doi:10.2807/eue.16.24.19892-pt
Quezada-Aguiluz, M., Lincopan, N., Cerdeira, L., Fuga, B., Silva, F., Barrera, B., Cifuentes, M., Bello-Toledo, H., Opazo-Capurro, A., & González-Rocha, G. (2020). Draft genome sequence of a multidrug-resistant KPC-2 and SRT-2 co-producing Serratia marcescens strain isolated from a hospitalised patient in Chile. *Journal of Global Antimicrobial Resistance*, 21, 1-2. doi:10.1016/j.jgar.2020.02.004

Sambrook, J., & Russel, D.W. (2004). *Molecular cloning: a laboratory manual*. 3 ed. New York; Cold Spring Harbor Laboratory Press pp 5.65-5.67.

Sandner-Miranda, L., Vinuesa, P., Soberón-Chávez, G., & Morales-Espinosa, R. (2016). Complete genome sequence of Serratia marcescens SmUNAM836, a nonpigmented multidrug-resistant strain isolated from a Mexican patient with obstructive pulmonary disease. *Genome Announcements*, 4 (1), e01417-15. doi:10.1128/genomeA.01417-15.

Silva, K.C., & Lincopan, N. (2012) Epidemiology of extended-spectrum beta-lactamases in Brazil: Clinical impact and implications for agribusiness. *Jornal Brasileiro de Patologia e Medicina Laboratorial*, 48 (2), 91-99. doi:10.1590/S1676-24442012000200004

Silva, K.E., Cayó, R., Carvalhaes, C.G, Sacchi, F.P.C., Rodrigues-Costa, F., Silva, A.C.R., Croda, J., Gales, A.C., & Simionatto, S. (2015). Coproduction of KPC-2 and IMP-10 in Carbapenem-Resistant *Serratia marcescens* Isolates from an Outbreak in a Brazilian Teaching Hospital. *Journal of Clinical Microbiology*, 53 (7), 2324-2328. doi:10.1128/JCM.00727-15.

Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D.L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outerson, K., Patel, J., Cavaleri, M., Cox, E.M., Houchens, C.R., Grayson, M.L., Hansen, P., Singh, N., Theuretzbacher, U., & Magrini, N. (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet Infectious Diseases*, 18 (3), 318-327. doi:10.1016/S1473-3099(17)30753-3

Yigit, H., Queenan, A.M., Anderson, G.J., Domenech-Sanchez, A., Biddle, J.W., & Steward, C.D. (2001). Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. *Antimicrobial agents and chemotherapy*, 45 (4), 1151-1161. doi:10.1128/AAC.45.4.1151-1161.2001